---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-168977"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T23:07:07.448828+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Kymera Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor at 2023 annual meeting

## Summary
- Elected Bruce Booth, Nello Mainolfi, John Maraganore, Elena Ridloff as Class III directors for three-year terms.
- Advisory vote on named executive officer compensation passed with 42.7M for, 1.5M against, 5K abstain.
- Ratified Ernst & Young as independent auditor for FY2023 with 46.6M for, 3.2K against.
- Broker non-votes: 2.46M on director elections and say-on-pay; none on auditor ratification.

## SEC filing metadata
- accession: 0001193125-23-168977
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312523168977/0001193125-23-168977-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312523168977/d516155d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-168977
- JSON: https://secwatch.observer/filing/0001193125-23-168977.json
- Plain text: https://secwatch.observer/filing/0001193125-23-168977.txt

## Key facts
- Shareholder Votes
  Kymera Therapeutics, Inc. shareholders approved Non-Binding, Advisory Vote on Compensation of the Company's Named Executive Officers at the 2023-06-15 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: The shareholders of the Company approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312523168977/0001193125-23-168977-index.htm
- Shareholder Votes
  Kymera Therapeutics, Inc. shareholders approved Election of Class III Director Nominees at the 2023-06-15 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: The shareholders of the Company elected Bruce Booth, D.Phil., Nello Mainolfi, Ph.D., John Maraganore, Ph.D. and Elena Ridloff, CFA as Class III directors of the Company, for a three-year term ending at the annual meeting of shareholders to be held in 2026 and until his or her successor has been duly elected and qualified or until his or her earlier death, resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312523168977/0001193125-23-168977-index.htm
- Shareholder Votes
  Kymera Therapeutics, Inc. shareholders approved Ratification of Appointment of Ernst & Young LLP as Independent Registered Public Accounting Firm at the 2023-06-15 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-06-15
  source text: The shareholders of the Company ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1815442/000119312523168977/0001193125-23-168977-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.